Sheri L. Koshman, BScPharm, ACPR, PharmD, Assistant Professor of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB.
Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, Associate Professor of Medicine; Division of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB.

Antiplatelet agents are the cornerstone of secondary prevention for patients who present with an ischemic stroke or transient ischemic attack (TIA). At present, monotherapy with acetylsalicylic acid (ASA) or clopidogrel or the combination regimen of ASA plus extended-release dipyridamole are recommended as first-line options in the stroke prevention guidelines. The combination of ASA and clopidogrel is not routinely recommended for secondary stroke prevention, since it has been shown to offer no therapeutic advantage and an increased risk of bleeding. The clear answer as to whether one or two antiplatelet agents are better for the secondary prevention of ischemic stroke events in older adults depends upon the combination of agents, as well as the monotherapy comparator.
Key words: stroke prevention, clopidogrel, acetylsalicylic acid, dipyridamole, antiplatelet agents.

Wilbert S. Aronow, MD, Department of Medicine, Divisions of Cardiology and Geriatrics, Westchester Medical Center/New York Medical College, Valhalla, NY; Clinical Professor of Medicine and Chief, Cardiology Clinic, Westchester Medical Center/New York Medical College, and Adjunct Professor of Geriatrics and Adult Development, Mount Sinai School of Medicine.

In older women, ischemic heart disease (IHD) is diagnosed if there is coronary angiographic evidence of significant IHD, a documented myocardial infarction, a typical history of angina with myocardial ischemia diagnosed by stress testing, or sudden cardiac death. Clinical manifestations of acute myocardial infarction in older women include dyspnea (the most common presenting symptom), chest pain, neurological symptoms and gastrointestinal symptoms. The prognosis of Q-wave myocardial infarction is not significantly different if the myocardial infarction is clinically recognized or unrecognized. IHD should be treated with intensive risk factor modification, antiplatelet therapy, beta-blockers and angiotensin-converting enzyme inhibitors.

Key words: ischemic heart disease, myocardial infarction, antiplatelet drugs, beta-blockers, angiotensin-converting enzyme inhibitors.

The most common cause of death in older women is ischemic heart disease (IHD). The prevalence of IHD is similar in older women compared to older men.¹ In one study of 2,464 women with an average age of 81 years, the prevalence of IHD was 41%.

D'Arcy L. Little, MD, CCFP
York Community Services, Toronto, ON

Introduction
Every year there are approximately 50,000 strokes in Canada. Currently, close to 300,000 Canadians are stroke survivors. As stroke is an age-related condition, the number of strokes is predicted to increase as the Canadian population ages. The resultant national cost, which is estimated at 2.7 billion annually, will also increase unless improvements are made to prevention and treatment.¹ Approximately 1 in 6 survivors of a first stroke experiences a recurrent stroke over the next 5 years, of which 25% are fatal within 28 days.² The above statistics suggest that attention to secondary stroke prevention would be important in reducing the morbidity, mortality and cost to society of stroke. The purpose of this article is to review the role of anti-platelet and anticoagulant agents in the secondary prevention of stroke.

Goals of Therapy
Therapeutic measures in secondary stroke prevention aim to prevent recurrent stroke or transient ischemic attacks, with the aim of preventing morbidity and mortality from incremental neurological deficits, as well as preventing associated cardiac ischemic events.